REGN

Regeneron Pharmaceuticals
D

REGN

546.88
USD
-0.69
(-0.13%)
مغلق
حجم التداول
13,988
الربح لكل سهم
35
العائد الربحي
0.32
P/E
14
حجم السوق
59,044,170,999
أصول ذات صلة
AMGN
AMGN
1.79
(0.60%)
298.52 USD
BIIB
BIIB
-1.170
(-0.88%)
132.000 USD
BMY
BMY
-0.525
(-1.10%)
47.080 USD
GILD
GILD
-0.760
(-0.68%)
110.760 USD
INCY
INCY
0.300
(0.44%)
68.470 USD
MRK
MRK
-1.370
(-1.66%)
81.010 USD
PFE
PFE
0.110
(0.43%)
25.440 USD
VRTX
VRTX
2.24
(0.49%)
459.27 USD
المزيد
الأخبار المقالات

العنوان: Regeneron Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).